PT-141 (Bremelanotide) Compounding Legal Status: FDA Approval, Label Details, and Safety
HealthRX.com
Compounded PT-141 is not Vyleesi or an FDA-approved drug
Key numbers
- 1.75 mgDose of the FDA-approved Vyleesi autoinjector, for premenopausal women with acquired HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Share of Vyleesi patients with nausea in pooled phase 3 trials, versus placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 18%Share of Vyleesi patients who stopped because of adverse reactions, versus placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- FDA-approved bremelanotide product / Vyleesi, NDA 210557, approved June 21, 2019
- Current NDA holder / Cosette Pharmaceuticals
- Approved form / 1.75 mg subcutaneous autoinjector, as needed
- Approved use / Acquired, generalized HSDD in premenopausal women only
- Compounded or research-use PT-141 / Not Vyleesi; not an FDA-approved drug
- FDA significant-safety-risk bulk list / Bremelanotide not listed
- HHS October 2026 draft peptide policy / Bremelanotide not among the six peptides
- Boxed warning / None
Is compounded PT-141 the same as Vyleesi?
No. Vyleesi is the FDA-approved bremelanotide product: a 1.75 mg subcutaneous injection in a prefilled autoinjector, prescription only, approved on June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][6][7]. Products sold as compounded or research-use 'PT-141' are not Vyleesi and are not FDA-approved drugs [1][2].
What is Vyleesi approved to treat?
Vyleesi is indicated for premenopausal women with acquired, generalized HSDD: low sexual desire that causes marked distress or interpersonal difficulty and is not due to a coexisting medical or psychiatric condition, relationship problems, or the effects of a medication or drug [1]. Acquired means the problem developed in a woman who previously had none; generalized means it occurs regardless of the type of stimulation, situation or partner [1]. The limitations are explicit: Vyleesi is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance [1].
How is Vyleesi taken?
The label gives the dose as 1.75 mg injected subcutaneously into the abdomen or thigh with the autoinjector, as needed, at least 45 minutes before anticipated sexual activity [1]. It allows no more than one dose in 24 hours and does not recommend more than 8 doses per month [1]. The label says to stop if there is no improvement after 8 weeks [1]. How long a single dose works is unknown [1].
What did the RECONNECT trials show?
Two identical 24-week randomized, double-blind, placebo-controlled trials (NCT02333071 and NCT02338960) randomized 1,267 premenopausal women with HSDD; 1,202 were in the efficacy analysis, and the mean age was 39 [8]. Mean change from baseline in the FSFI desire domain was 0.5 with Vyleesi versus 0.2 with placebo in Study 1 and 0.6 versus 0.2 in Study 2 [1]. The trials found no significant difference between groups in the number of satisfying sexual events [8].
Does Vyleesi have a boxed warning or a REMS?
No. The label carries no boxed warning, and no risk evaluation and mitigation strategy (REMS) appears in the label or in the 2019 approval letter [1][6].
What does the label say about blood pressure?
Vyleesi transiently raises blood pressure and lowers heart rate after each dose [1]. The maximal increases in clinical studies were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal, not average, figures. In a separate open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk of cardiovascular disease; the label says to consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1].
What adverse reactions does the label list?
In the pooled phase 3 trials: nausea 40.0% versus 1.3% on placebo, flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4%, headache 11.3% versus 1.9%, and vomiting 4.8% versus 0.2% [1]. Nausea was highest after the first dose (21% of patients) and fell to about 3% with later doses; 13% used an anti-nausea medicine and 8% stopped the trials because of nausea [1]. Overall, 18% of Vyleesi patients versus 2% of placebo patients discontinued because of adverse reactions, and serious adverse reactions occurred in 1.1% versus 0.5% [1].
Focal hyperpigmentation of the face, gums or breasts was reported by 1% of patients taking up to 8 doses a month versus none on placebo; in another study, 38% developed it after 8 days of daily dosing and a further 14% after 8 more consecutive days [1]. Risk is higher in darker skin and with daily dosing, resolution was not confirmed in all patients, and the label says to consider discontinuing Vyleesi if hyperpigmentation develops [1]. One case of acute hepatitis with transaminases above 40 times the upper limit of normal occurred after 10 doses over a year in an open-label extension; another cause was not identified, so a role for Vyleesi could not be excluded [1].
Which interactions does the label flag?
Vyleesi may significantly decrease the systemic exposure of oral naltrexone, and the label says to avoid it with oral naltrexone-containing products intended to treat alcohol or opioid addiction because of the severe consequence of naltrexone treatment failure [1]. Vyleesi may also slow gastric emptying and reduce absorption of oral medicines; the label says to avoid it with oral drugs that depend on threshold concentrations, such as antibiotics, and to consider skipping it when a quick effect from an oral medicine such as indomethacin is wanted [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1].
What does the label say about pregnancy?
The label says to discontinue Vyleesi if pregnancy is suspected and to use effective contraception; in dogs, fetal harm occurred at exposures at least 16 times the human dose by AUC [1]. Section 8 and the patient information are being revised under a labeling supplement FDA approved on October 22, 2026 [9].
Does bremelanotide appear on FDA's compounding lists?
FDA publishes a list of bulk drug substances that may present significant safety risks when compounded, with content dated April 22, 2026 [3]. Bremelanotide is not on that list, and it does not appear in any category on FDA's bulk-substance lists [3][4]. HHS's October 2026 draft enforcement-discretion policy names six peptides; bremelanotide is not one of them [5]. None of that makes a compounded PT-141 product an FDA-approved drug [2].
Can men or postmenopausal women use bremelanotide?
The label says Vyleesi is not indicated for HSDD in men or postmenopausal women, and not to enhance sexual performance [1]. Any such use is outside the label, and compounded products are not FDA-approved drugs [1][2]. The safety data in the two placebo-controlled trials came from 1,247 premenopausal women [1].
What this means for compounded PT-141
Vyleesi is the FDA-approved bremelanotide product, at a fixed 1.75 mg dose in an autoinjector [1]. Compounded PT-141 is a different regulatory item and is not an FDA-approved drug [2]. More on the product: PT-141.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Is PT-141 FDA-approved?
Is compounded PT-141 legal?
Does Vyleesi have a boxed warning or a REMS?
How much does Vyleesi raise blood pressure?
Can men take bremelanotide?
Is compounded PT-141 the same as Vyleesi?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Is the PT-141 peptide legal?
No legal ruling is stated, but compounded PT-141 is not an FDA-approved drug, and FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Bremelanotide is not on FDA's significant-safety-risk bulk list and is not among the six peptides in HHS's October 2026 draft policy, though neither fact makes a compounded product FDA-approved.
Has bremelanotide been approved by the FDA?
Yes, as Vyleesi, approved on June 21, 2019 under NDA 210557 for premenopausal women with acquired, generalized HSDD. Vyleesi is a 1.75 mg subcutaneous autoinjector used as needed. Compounded or research-use PT-141 is not Vyleesi and is not an FDA-approved drug.
What happens if you take PT-141 too often?
No effects of dosing beyond these limits are described. The label allows no more than one dose in 24 hours and does not recommend more than 8 doses per month. Focal hyperpigmentation of the face, gums or breasts was reported by 1% of patients taking up to 8 doses a month, and risk is higher with daily dosing, so the label says to consider stopping if it develops.
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Drugs@FDA: FDA-Approved Drugs.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- U.S. Food and Drug Administration.